Summary recommendations for de novo T-ALL and T-LL
| Recommendations . |
|---|
| 1. Offer an open clinical trial if available |
| 2. Dexamethasone-based induction |
| 3. Early intensified therapy including a 4-drug induction with anthracycline and multiagent augmented consolidation, including cyclophosphamide |
| 4. Patients with ETP ALL should be treated the same as their non-ETP counterparts |
| 5. Risk stratification in T-ALL primarily based on bone marrow MRD; risk stratification in T-LL primarily based on radiographic response |
| 6. Only consider CRT in patients with overt CNS disease (CNS3) at diagnosis |
| 7. If available, consider including nelarabine in the treatment of all patients with T-ALL and T-LL |
| 8. HDMTX is not needed for T-ALL, if CMTX and nelarabine are included in the backbone |
| 9. Consider HSCT for patients with persistent disease after 3 mo of intensive therapy |
| Recommendations . |
|---|
| 1. Offer an open clinical trial if available |
| 2. Dexamethasone-based induction |
| 3. Early intensified therapy including a 4-drug induction with anthracycline and multiagent augmented consolidation, including cyclophosphamide |
| 4. Patients with ETP ALL should be treated the same as their non-ETP counterparts |
| 5. Risk stratification in T-ALL primarily based on bone marrow MRD; risk stratification in T-LL primarily based on radiographic response |
| 6. Only consider CRT in patients with overt CNS disease (CNS3) at diagnosis |
| 7. If available, consider including nelarabine in the treatment of all patients with T-ALL and T-LL |
| 8. HDMTX is not needed for T-ALL, if CMTX and nelarabine are included in the backbone |
| 9. Consider HSCT for patients with persistent disease after 3 mo of intensive therapy |